大信专审字[2025]第 5-00025 号 大信会计师事务所（特殊普通合伙） 深圳信立泰药业股份有限公司 非经营性资金占用及其他关联资金往 来情况汇总表的专项审计报告 WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 非经营性资金占用及其他关联资金往来情况汇总表的 专项审计报告 大信专审字[2025]第 5-00025 号 深圳信立泰药业股份有限公司全体股东： 我们接受委托，审计了深圳信立泰药业股份有限公司（以下简称"贵公司"）的财务 ...

深圳信立泰药业股份有限公司 募集资金存放与实际使用情况审核报告 大信专审字[2025]第 5-00026 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 募集资金存放与实际使用情况审核报告 大信专审字[2025]第 5-00026 号 深圳信立泰药业股份有限公司全体股东： 我们接受委托，对后附的深圳信立泰药业股份有限公司（以下简称"贵公司"）《2024 年度募集资金存放与使用情况的专项报告》（以下 ...

二、募集资金基本情况 华英证券有限责任公司 关于深圳信立泰药业股份有限公司 2024 年度募集资金存放与使用情况的核查意见 根据中国证监会发布的《证券发行上市保荐业务管理办法》《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《深圳 证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关规定，华英证 券有限责任公司（以下简称"华英证券"或"保荐机构"）作为深圳信立泰药业 股份有限公司（以下简称"信立泰"或"公司"）的持续督导机构，对信立泰 2024 年度募集资金的存放与使用情况进行了核查，具体情况如下： 一、华英证券的核查工作 华英证券审阅了公司董事会关于募集资金年度存放与使用情况的专项报告、 大信会计师事务所（特殊普通合伙）出具的公司募集资金存放与使用情况的鉴证 报告；查看募集账户的资金使用明细账；从募集资金专户所在银行取得募集资金 专户银行对账单；并与公司财务总监、董事会秘书等人员沟通，核查了募集资金 的使用与项目进度情况。 1、实际募集资金金额、资金到位时间 经中国证券监督管理委员 ...

深圳信立泰药业股份有限公司 审 计 报 告 大信审字[2025]第 5-00030 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No.1 Zhichun Road,Haidian Dist. Beijing,China,100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 审计报告 大信审字[2025]第 5-00030 号 深圳信立泰药业股份有限公司全体股东： 一、审计意见 我们审计了深圳信立泰药业股份有限公司（以下简称"贵公司"）的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、 ...

一、 基本情况 （一） 个人工作履历、专业背景及兼职情况说明 刘来平，中国国籍，无境外居留权，男，1970 年生，法学博士，现任公司独 立董事，董事会薪酬与考核委员会召集人、提名委员会委员、审计委员会委员。 1993 年 7 月至 2003 年 5 月，历任深圳市龙岗区人民法院书记员、代理审判 员、审判员、执行庭副庭长；2003 年 5 月至 2013 年 8 月，历任深圳市中级人民 法院代理审判员、审判员、副处长、庭长、审判委员会委员。自 2014 年起担任 深圳迈瑞生物医疗电子股份有限公司中国区法律事务部总经理等职务，现任迈瑞 医疗副总经理。2022 年 6 月至 2024 年 1 月任深圳迈瑞科技控股有限责任公司董 事。2014 年 9 月至 2021 年 9 月任广东冠豪高新技术股份有限公司独立董事， 2016 年 9 月至 2022 年 10 月任深圳市海王生物工程股份有限公司独立董事。2020 年 1 月至今任深圳信立泰药业股份有限公司独立董事。 （二） 是否存在影响独立性的情况说明 深圳信立泰药业股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人作为深圳信立泰药业股份有限公 ...

深圳信立泰药业股份有限公司董事会 关于独立董事独立性自查情况的专项报告 根据《中华人民共和国公司法》、《上市公司独立董事管理办法》、《深圳 证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》以及《深圳信立泰药业股份有限公司章程》等有关规 定，深圳信立泰药业股份有限公司（下称"公司"）董事会对公司全体在任独立 董事的独立性情况进行评估，并出具专项意见如下： 经核查，公司在任独立董事朱厚佳先生、刘来平先生、王学恭先生的任职经 历以及其签署的相关自查情况报告等文件，董事会认为，上述人员未在公司担任 除独立董事以外的任何职务，也未在公司主要股东公司担任任何职务，与公司及 主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，亦不 存在其他影响独立董事独立性的情况。 公司独立董事符合《上市公司独立董事管理办法》、《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》等相关法律法规、规范性 文件以及《公司章程》中对独立董事独立性的相关要求。 深圳信立泰药业股份有限公司 董事会 二〇二五年三月二十九日 ...

深圳信立泰药业股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 作为公司独立董事，经自查，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司及主要股东之间不存在利害关系 或其他可能妨碍本人进行独立客观判断的关系，亦不存在其他影响独立董事独立 性的情况。本人任职符合《上市公司独立董事管理办法》第六条等规定的独立性 要求，不存在影响独立性的情况。 二、 年度履职概况 | 独立董事 | 应参加 | 现场 | 以通讯方式 | 委托 | 缺席次数 | 是否连续 两次未亲自 | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 会议次数 | 出席次数 | 参加次数 | 出席次数 | | | | | | | | | | 参加会议 | | 朱厚佳 | 5 | 2 | 3 | 0 | 0 | 否 | （一） 2024 年，公司共召开 5 次董事会，具体出席情况见下表： 本人作为深圳信立泰药业股份有限公司（下称"公司"）独立董事，2024 年 度，严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证券交易所 上市公司自 ...

深圳信立泰药业股份有限公司 王学恭，中国国籍，无境外居留权，男，1972 年生，大学本科，具备医药工 程师资格，现任公司独立董事，董事会提名委员会召集人、薪酬与考核委员会委 员。 1993 年 7 月至 2010 年 2 月，历任华北制药集团有限责任公司技术员、总经 理办公室副主任、营销战略部部长、资本运营部部长；2010 年 2 月至 2014 年 4 月任中国医药企业管理协会副秘书长，2014 年 4 月至今任中国医药企业管理协 会副会长。2016 年 4 月至 2021 年 5 月任人福医药集团股份公司独立董事，2017 年 5 月至 2023 年 6 月任北京诚益通控制工程科技股份有限公司独立董事，2020 年 9 月至今任迪哲（江苏）医药股份有限公司独立董事，2022 年 5 月至今任浙 江华海药业股份有限公司独立董事。2021 年 12 月至今任深圳信立泰药业股份有 限公司独立董事。 2017 年 5 月至 2024 年 12 月任中国医药包装协会副会长，2018 年 7 月至今 任三一创新（北京）投资管理有限公司合伙人、投资决策委员会成员，2018 年 9 月至今任杭州尚健生物技术有限公司董事， ...

Product Development and Innovation - In 2024, the company launched two new drugs, Xintaitin and Fulitan, which have been approved for market and included in the medical insurance negotiations, establishing a solid foundation for sustainable development[11]. - The company has four exclusive and high-quality innovative patented products, with four new products currently under review for market approval and three in phase III clinical trials[11]. - The company is focusing on chronic disease management, particularly in the hypertension sector, with multiple innovative products launched and a rich pipeline of ongoing research[11]. - The company is conducting international multi-center phase II clinical trials for JK07 in the US, Canada, and China, showing promising safety and efficacy signals[11]. - The company has made significant progress in early-stage projects in both chemical and biological drug series, indicating steady advancement in innovation[11]. - The innovative drug Xinlitai (Alisartan) has been included in the national medical insurance directory after three rounds of negotiations, enhancing its market potential[39]. - The new product sales, including Xinlitai and Fuzhitai, have shown rapid growth, contributing to the company's sustained growth momentum[46]. - The innovative drug Ennaruo (HIF-PHI) was included in the national medical insurance directory in 2023, targeting anemia in non-dialysis chronic kidney disease patients[42]. - The clinical research for the innovative drug S086 has shown significant dose-dependent blood pressure reduction, with reductions of 25.07 mmHg and 28.22 mmHg for 240 mg and 480 mg doses respectively after 12 weeks[40]. - Four key R&D projects have successfully completed their milestone goals, with S086 (hypertension) passing technical review and several other drugs in the CDE review process[50]. - The company plans to submit 7 drug IND applications and 2 new product market applications in 2024, along with 5 clinical trial approvals and 5 registration certificates[54]. - The company has been granted 69 patents, including 46 invention patents, and has submitted 178 new patent applications, indicating a strong focus on innovation[55]. - The company is actively exploring AI technology applications in drug discovery and clinical research to enhance efficiency and decision-making[52]. - The company has established a comprehensive chronic disease product pipeline, focusing on hypertension, heart failure, and chronic kidney disease, addressing unmet clinical needs[59]. - The Gstream® drug-eluting peripheral artery stent system has entered the "green channel" approval process, marking a significant advancement in medical device innovation[54]. - The company is expanding its product pipeline with new medical devices, including drug-eluting stents and balloon catheters for cardiovascular interventions[86]. - The company is actively developing new drug compositions, including a combination drug for hypertension and heart failure, with applications expected in 2024[92]. Financial Performance - The company's operating revenue for 2024 reached ¥4,012,231,593.39, representing a 19.22% increase compared to ¥3,365,343,342.73 in 2023[27]. - The net profit attributable to shareholders for 2024 was ¥601,569,140.20, a 3.71% increase from ¥580,066,240.84 in 2023[27]. - The net cash flow from operating activities increased by 41.32% to ¥1,186,258,420.75 in 2024, up from ¥839,442,557.56 in 2023[27]. - Total assets at the end of 2024 were ¥10,465,603,624.18, an 11.38% increase from ¥9,396,672,754.02 at the end of 2023[27]. - The company reported a basic earnings per share of ¥0.54 for 2024, a 3.85% increase from ¥0.52 in 2023[27]. - The net profit after deducting non-recurring items for 2024 was ¥570,202,532.66, an 8.43% increase from ¥525,862,387.30 in 2023[27]. - The pharmaceutical manufacturing sector contributed ¥3,706,825,061.65, accounting for 92.39% of total revenue, with a year-on-year growth of 17.69%[66]. - The medical device segment saw a significant increase of 41.68%, generating ¥305,406,531.74, up from ¥215,562,619.48 in the previous year[66]. - The company achieved a gross margin of 73.40% in the pharmaceutical manufacturing sector, an increase of 4.00% year-on-year[68]. - Sales volume in the pharmaceutical manufacturing sector increased by 30.79% to 165,585,451 boxes in 2024, compared to 126,600,060 boxes in 2023[70]. - The company’s total sales revenue from the top five customers amounted to ¥2,053,359,796.30, representing 51.17% of the annual total sales[76]. Strategic Focus and Market Expansion - The company is focusing on the cardiovascular disease market, which has over 300 million patients in China, indicating significant growth potential[36]. - The company is expanding its product pipeline in chronic disease areas, including hypertension, heart failure, and metabolic diseases, with several competitive products in development[37]. - The company plans to leverage inter-departmental collaboration to enhance its offerings in various therapeutic areas, including oncology and mental health[37]. - The company has a strategic focus on innovation in pharmaceuticals and medical devices, aiming to provide comprehensive treatment solutions[37]. - The company aims to deepen its focus on the cardiovascular treatment field, establishing a strong customer base and brand reputation in specific segments[62]. - The company is committed to building a collaborative innovation ecosystem, integrating technology and talent development to enhance core competitiveness[52]. - The company is actively exploring new chronic disease management models and expanding its market presence through diversified channel strategies[47]. - The company is committed to internationalization and aims to establish itself as a leading innovative pharmaceutical enterprise based in China[128]. - The company is actively participating in volume-based procurement to strengthen its market competitiveness in the generic drug sector[129]. - The company plans to enhance its product commercialization capabilities and increase product penetration rates in 2025[129]. - Market expansion plans include entering two new international markets by the end of the year, targeting a 10% increase in overall market share[6]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 500 million RMB allocated for potential deals[7]. Governance and Management - The company has established a comprehensive governance structure, with independent operation of the board of directors and supervisory board[162]. - The board of directors operates transparently and effectively, with independent directors playing a crucial role in protecting minority shareholder interests[144]. - The supervisory board consists of three members, including one employee representative, ensuring effective oversight of the company's operations[145]. - The company has implemented an employee stock ownership plan to enhance employee motivation and promote long-term sustainable development[146]. - The controlling shareholder has pledged 15.679 million shares, representing 24.68% of their total holdings and 14.06% of the company's total shares, indicating a relatively low pledge ratio[151]. - The company maintains a completely independent operational structure from its controlling shareholder, with separate assets, personnel, and financial management[158]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, continuously optimizing it[146]. - The company actively engages with stakeholders, ensuring a balance of interests among shareholders, employees, and the community[148]. - The company has a dedicated financial department that operates independently, ensuring no interference from the controlling shareholder in financial activities[164]. - The company has held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[143]. Research and Development - The company invested 1.017 billion yuan in R&D in 2024, accounting for 25.35% of its revenue[48]. - R&D investment amounted to ¥1,017,122,792.10 in 2024, down 2.90% from ¥1,047,475,745.11 in 2023[94]. - R&D investment as a percentage of revenue fell to 25.35% from 31.13%, a decrease of 5.78%[94]. - R&D personnel decreased to 755, a decline of 3.70% from 784[93]. - The company is prioritizing the development of smart medical devices, which are anticipated to improve patient outcomes and operational efficiency in healthcare settings[92]. - The company is focusing on optimizing production processes and enhancing operational efficiency to manage rising costs[133]. - The company anticipates risks related to high R&D costs, long cycles, and potential policy changes affecting drug pricing[132]. Sustainability and Corporate Responsibility - The company is committed to sustainability initiatives, aiming for a 40% reduction in carbon emissions by 2025[186]. - The company has committed to green development and resource conservation, contributing to sustainable development goals[148]. - The company has established a "Market Value Management System" to enhance investment value and shareholder returns, approved on March 23, 2025[135]. - The "Quality and Return Dual Improvement" action plan aims for high-quality development and investor returns, with a focus on chronic disease innovation[136]. - The company has actively implemented the "Quality and Return Dual Improvement" action plan, enhancing compliance and operational efficiency[137].

Group 1 - The core viewpoint is that the healthcare ETF Taikang (159760) has seen a 1.75% increase, driven by a recovering macroeconomic environment, which is expected to boost the growth rate of healthcare service revenues [1] - The Taikang healthcare ETF closely tracks the National Index of Public Health and Healthcare, which reflects the market performance of publicly listed companies in the public health and healthcare sector in the A-share market [1] - The top ten weighted stocks in the National Index of Public Health and Healthcare as of February 28, 2025, include Mindray Medical, Hengrui Medicine, WuXi AppTec, and others, accounting for a total of 52.4% of the index [1] Group 2 - Guotai Junan Securities indicates that in 2024, external consumption and medical insurance environments are under pressure, leading to a decline in the unit price of specialized medical services such as ophthalmology and dentistry, resulting in slowed growth [2] - Despite the slowdown in revenue growth, the demand for medical services remains strong, and as the macro economy gradually recovers, residents' payment capabilities and consumer confidence are expected to improve, leading to a rebound in revenue growth [2] - The rapid development of AI technology is expected to bring significant changes to the healthcare industry, with the healthcare ETF Taikang (159760) likely to continue benefiting from this trend [2]